跳至主要内容
临床试验/NCT01245621
NCT01245621已完成不适用

Early vs. Later Palliative Cancer Care: Clinical and Biobehavioral Outcomes

Dartmouth-Hitchcock Medical Center14 个研究点 分布在 1 个国家目标入组 360 人开始时间: 2010年10月最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
已完成
入组人数
360
试验地点
14
主要终点
Change in patient's quality of living over time

研究概览

简要总结

ENABLE III is a randomized clinical trial that evaluates a phone-based palliative care intervention designed to improve quality of life, mood, and symptom management for patients with an advanced stage cancer and their caregivers.

The primary aims of this clinical trial are to determine whether a palliative care intervention (introduced immediately or 12 weeks after diagnosis) can improve survival, quality of life, mood, symptom intensity and end-of-life care.

详细描述

In 2008, cancer claimed more than 565,000 American lives -1,500 people a day. Palliative care strives to improve quality of life (QOL) and to prevent "bad deaths" by providing expert, interdisciplinary care to manage the effects of disease and treatment. Effective end-of-life (EOL) care depends upon proactive, patient-centered interventions to prepare patients and families for the challenges of terminal illness. We were able to demonstrate the feasibility and efficacy of a concurrent oncology palliative care (COPC) intervention in improving quality of life and mood in our previous studies ENABLE I and ENABLE II; however, a number of gaps in our knowledge remain.

Patients will be randomized to begin the intervention either immediately or 12 weeks after a new diagnosis of advanced or recurrent cancer. This phone-based intervention consists of: 1) an Advanced Practice Palliative Care Nurse Interventionist instituting 1a) a 6-session manualized patient curriculum- Charting Your Course (CYC), 1b) a 3-session manualized, caregiver curriculum- the Creativity Optimism Planning Expert information (COPE) program, and 1c) on-going patient and caregiver follow up; and 2) Palliative Care Team Comprehensive Assessment & Management.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Supportive Care
盲法
Single (Outcomes Assessor)

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

研究组 & 干预措施

Early entry group

Active Comparator

Early entry group will begin the intervention at time of diagnosis of advanced cancer

干预措施: Early palliative care intervention (Behavioral)

Later entry group

Active Comparator

Later entry group will begin the intervention 12 weeks after enrollment in the study.

干预措施: Later entry group (Behavioral)

结局指标

主要结局

Change in patient's quality of living over time

时间窗: baseline, 6,12,18,24,36 and every 12 weeks until death or end of study

Quality of living assessments will include quality of life (QOL), mood, and symptom intensity measures using the following measures: * Functional Assessment of Chronic Illness Therapy-Palliative Care (FACIT-Pal): * Quality of Life at End of Life (QUAL-E). * Center for Epidemiological Study- Depression (CES-D).

Change in caregiver quality of life, burden and grief over time

时间窗: baseline, 6,12,18,24,36, and every 12 weeks until patient death or end of study

Caregiver burden and QOL will be measured using: * Quality of Life- Cancer- a self-report measure of QOL for caregivers of patients with cancer. * Montgomery Borgatta Caregiver Burden Scale -a self-report measure of caregiver burden. * Center for Epidemiological Study- Depression CESD is a measure of depressive symptoms. * Functional Assessment of Chronic Illness Therapy - Spiritual Module (FACIT-Sp) - a measure of spiritual well-being developed for persons with chronic illness. * Prigerson Inventory of Complicated Grief-Short form (ICG-SF) embedded in the Quality of Death and Dying (QODD).

Quality of end of life care

时间窗: chart review at time of death and caregiver proxy interview 2-3 months after patient death

End of life (EOL) Care Data Collection Form: This form is used to collect information about the quality of EOL care and circumstances surrounding the last 48 hours of life for patients who die in hospital, nursing home, or home. Quality of Dying and Death Measure (QODD). The QODD is a structured interview conducted with a caregiver to measure the quality of a patient's last week of life. The interview assesses the caregiver's perception of patient symptoms, preferences, and satisfaction with care.

Estimate and compare the hazard ratios and median survival before and after 1 year from enrollment

时间窗: From enrollment until patient death or end of study

We hypothesize that Early entry patients will have longer overall survival at one year compared with Later entry patients.

次要结局

  • Determine feasibility of enrolling less common solid tumors and hematologic malignancies.(Estimated recruitment period of 2 years)
  • Mediating mechanisms and moderators of the concurrent palliative care intervention.(baseline, 6,12,18,24,36 weeks and every 12 weeks until death or end of study)
  • Explore patterns of stress (diurnal salivary and plasma cortisol) and immune biomarkers (lymphocyte subsets and cytokines)(Baseline, 12, and 24 weeks)
  • Examine the relations among quality of life, mood, symptoms, survival, stress and immune biomarkers.(Baseline, 12, and 24 weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (14)

Loading locations...

相似试验

终止
3 期
A Study Evaluating Regorafenib Following Completion of Standard Chemotherapy for Patients With Colon CancerStage III (IIIB or IIIC) Colon Cancer
NCT02664077NSABP Foundation Inc34
已完成
3 期
Radiation Therapy With or Without Chemotherapy in Patients With Stage I-IIA Cervical Cancer Who Previously Underwent SurgeryCervical AdenocarcinomaCervical Adenosquamous CarcinomaCervical Squamous Cell Carcinoma, Not Otherwise SpecifiedStage I Cervical Cancer AJCC v6 and v7Stage IA Cervical Cancer AJCC v6 and v7Stage IB Cervical Cancer AJCC v6 and v7Stage IIA Cervical Cancer AJCC v7
NCT01101451GOG Foundation340
已完成
3 期
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder UrotheliumStage III Bladder CancerStage IV Bladder CancerTransitional Cell Carcinoma of the Bladder
NCT00028756European Organisation for Research and Treatment of Cancer - EORTC285
已完成
3 期
Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Stage III or Stage IV Low-Grade Non-Hodgkin's LymphomaStage III Grade 1 Follicular LymphomaStage III Grade 2 Follicular LymphomaStage III Grade 3 Follicular LymphomaStage III Small Lymphocytic LymphomaStage IV Grade 1 Follicular LymphomaStage IV Grade 2 Follicular LymphomaStage IV Grade 3 Follicular LymphomaStage IV Small Lymphocytic Lymphoma
NCT00003204National Cancer Institute (NCI)515
已完成
3 期
A Study of Capecitabine (Xeloda) in Combination Chemotherapy Versus Surgery Alone in Participants With Gastric CancerGastric Cancer
NCT02560974Hoffmann-La Roche1,035